Association of baseline CEA, VEGF, and soluble VEGF receptor-2 with treatment outcomes in two randomized phase III trials of cediranib in metastatic colorectal cancer (mCRC).Hans‐Joachim Schmoll, J.M. Jürgensmeier, Sara Morgan et al.|Journal of Clinical Oncology|2011Cited by 7
Use of KRAS mutation status to predict clinical outcomes in patients with metastatic colorectal cancer (mCRC) treated with the VEGF signaling inhibitor cediranib.J.M. Jürgensmeier, Jeff Smith, P. M. Hoff et al.|Journal of Clinical Oncology|2011Cited by 3